20:34 , Jul 14, 2017 |  BioCentury  |  Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
07:00 , Aug 4, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Neurotensin (NTS)-based PET imaging agents for diagnosing and monitoring treatment responses of neurotensin receptor 1 (NTSR1)-positive tumors

Imaging TECHNOLOGY: PET Neurotensin-based PET imaging agents could help diagnose and monitor treatment-response for NTSR1-positive cancers. Two agents, consisting of a six-amino acid peptide derived from the N-terminus of neurotensin conjugated via linkers to a...
07:00 , Jun 16, 2016 |  BC Innovations  |  Translation in Brief

Fat links

Although neurotensin promotes fat uptake, satiety and cancer cell growth, the hormone's instability has made it difficult to measure in the clinic or connect directly to human disease. Using an assay from sphingotec GmbH on...
07:00 , May 26, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Neurotensin (NTS); neurotensin receptor 1 (NTSR1); proneurotensin

Endocrine/metabolic disease INDICATION: Obesity Human sample and mouse studies suggest inhibiting NTS- NTSR1 signaling could help treat obesity. In 4,632 obesity patients and healthy volunteers, high fasting plasma levels of the NTS precursor proneurotensin were...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Company News

Ipsen, 3B Pharmaceuticals deal

3B granted Ipsen exclusive, worldwide rights to develop and commercialize radiopharmaceuticals targeting the neurotensin (NTS) receptor. Ipsen will develop the preclinical compounds to treat pancreatic adenocarcinoma and potentially other cancers. 3B will receive an undisclosed...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations...
07:00 , Mar 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neurotensin (NTS) In vitro and rodent studies suggest a conjugate of NTS and the brain-penetrating peptide Angiopep could help treat pain. In a mouse...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

Angiochem preclinical data

In rat models of neuropathic and bone cancer pain, 0.05 mg/kg ANG2002 significantly reduced pain behaviors vs. vehicle-treated controls. Angiochem said ANG2002's analgesic efficacy was similar to that of morphine in a tail flick pain...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neurotensin receptor 1 (NTSR1); NTSR2 A study in rats identified a derivative of an analgesic neurotensin hexapeptide that could help treat pain. In four...
07:00 , Apr 29, 2010 |  BC Innovations  |  Targets & Mechanisms

TREK-ing after a new antidepressant

French researchers have developed a peptide inhibitor of TREK-1 that they think produces antidepressant effects much faster than marketed selective serotonin reuptake inhibitors. 1 NeuroSearch A/S is now considering moving into lead optimization with an...